sur Eckert & Ziegler Strahlen- Und Medizintechnik AG (isin : DE0005659700)
Eckert & Ziegler Reports Strong Growth in First Nine Months of 2024
Eckert & Ziegler SE experienced notable growth in the first nine months of 2024, with sales rising by 17% to €215.5 million. The company's adjusted EBIT increased by 24% to reach €46.7 million. Net income, including continuing and discontinued operations, grew by 15% to €23.4 million, equivalent to €1.12 per share.
The Medical segment reported a 26% increase in sales, reaching €104.5 million. This growth was mainly driven by the pharmaceutical radioisotope business. Similarly, the Isotope Products segment saw a 10% rise in sales, totaling €111.0 million, benefitting from a shift towards higher-margin products.
For the full financial year 2024, Eckert & Ziegler's Executive Board projects revenues around €265 million and an EBIT from continuing operations of approximately €55 million.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Eckert & Ziegler Strahlen- Und Medizintechnik AG